docruДоктор.РуTitle1727-23782713-2994ООО "ГК "РУСМЕДИКАЛ"10.31550/1727-2378-2023-22-5-49-53docru-196Research ArticleГИНЕКОЛОГИЯGYNECOLOGYПреждевременная недостаточность яичников: последствия для здоровья и стратегии заместительной гормональной терапииPremature Ovarian Insufficiency: Long-Term Health Consequences and Hormone Replacement Therapy Strategieshttps://orcid.org/0000-0002-8584-5517АверковаВ. Г.AverkovaV. G.

Виктория Геннадьевна Аверкова, аспирант

отделение гинекологической эндокринологии

117997; ул. Академика Опарина, д. 4; Москва

117997; 4 Academician Oparin Str.; Moscow

buch1202@mail.ruhttps://orcid.org/0000-0003-3504-2406ДонниковА. Е.DonnikovA. E.

Андрей Евгеньевич Донников, к. м. н., заведующий лабораторией

лаборатория молекулярно-генетических методов

117997; ул. Академика Опарина, д. 4.; Москва

117997; 4 Academician Oparin Str.; Moscow

onnikov@dna-technology.ruФГБУ «Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова» Министерства здравоохранения Российской ФедерацииРоссияV.I. Kulakov National Medical Scientific Centre of Obstetrics, Gynecology and Perinatal MedicineRussian Federation202318022025225ГИНЕКОЛОГИЯ4953Copyright © Аверкова В.Г., Донников А.Е., 20252025Аверкова В.Г., Донников А.Е.Averkova V.G., Donnikov A.E.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://docru.elpub.ru/jour/article/view/196   Цель обзора

   Цель обзора: анализ современных взглядов на патогенез осложнений и отдаленных последствий дефицита половых гормонов среди пациенток с преждевременной недостаточностью яичников (ПНЯ), а также возможностей и стратегий заместительной гормональной терапии (ЗГТ) для их лечения и профилактики.

   Основные положения

   Основные положения. Последствиями дефицита половых гормонов при ПНЯ являются не только краткосрочные клинические проявления, схожие с климактерическими, но и отдаленные негативные исходы для общего здоровья и жизни. ЗГТ обладает терапевтическим и профилактическим потенциалом в отношении всех клинических аспектов ПНЯ. Однако выработанные в настоящее время стандартные терапевтические стратегии не всегда позволяют полностью купировать симптомы ПНЯ и обеспечить надежную профилактику осложнений.

   Заключение

   Заключение. Выбор адекватных доз и состава ЗГТ, наряду с междисциплинарным подходом в лечении ПНЯ, позволят нивелировать связанные с ней риски и обеспечить высокое качество жизни пациенток.

   Aim

   Aim: analysis of modern views on the pathogenesis of complications and long-term consequences of sex hormone deficiency among patients with premature ovarian insufficiency (POI), as well as the possibilities and strategies of hormone replacement therapy (HRT) for their treatment and prevention.

   Key Points

   Key Points. The consequences of a sex hormones deficiency in women with POI are not only short-term clinical manifestations similar to menopause, but also long-term negative outcomes for general health and life. HRT has therapeutic and prophylactic potential for all clinical aspects of the disease. However, the currently developed standard therapeutic strategies do not always allow to completely stop the symptoms of POI and ensure reliable prevention of complications in the future.

   Conclusion

   Conclusion. The choice of adequate doses and composition of HRT, along with an interdisciplinary approach to the treatment of this pathology, will make it possible to level the associated risks and ensure a high quality of life for patients.

преждевременная недостаточность яичниковзаместительная гормональная терапиясердечно-сосудистые заболеванияостеопорозгенитоуринарный менопаузальный синдромpremature ovarian insufficiencyhormone replacement therapycardiovascular diseasesosteoporosisgenitourinary menopausal syndromeАвторы заявляют об отсутствии внешнего финансирования при проведении исследования и написании статьиThe authors declare that there is no external funding for the exploration and analysis workReferencesEuropean Society for Human Reproduction and Embryology (ESHRE) Guideline Group on POI, Webber L., Davies M. et al. ESHRE Guideline: management of women with premature ovarian insufficiency. Hum. Reprod. 2016;31(5):926–937. DOI: 10.1093/humrep/dew027European Society for Human Reproduction and Embryology (ESHRE) Guideline Group on POI, Webber L., Davies M. et al. ESHRE Guideline: management of women with premature ovarian insufficiency. Hum. Reprod. 2016;31(5):926–937. DOI: 10.1093/humrep/dew027Panay N., Anderson R.A., Nappi R.E. et al. Premature ovarian insufficiency: an International Menopause Society White Paper. Climacteric. 2020;23(5):426–446. DOI: 10.1080/13697137.2020.1804547Panay N., Anderson R.A., Nappi R.E. et al. Premature ovarian insufficiency: an International Menopause Society White Paper. Climacteric. 2020;23(5):426–446. DOI: 10.1080/13697137.2020.1804547Torrealday S., Kodaman P., Pal L. Premature Ovarian Insufficiency — an update on recent advances in understanding and management. F1000Res. 2017;6:2069. DOI: 10.12688/f1000research.11948.1Torrealday S., Kodaman P., Pal L. Premature Ovarian Insufficiency — an update on recent advances in understanding and management. F1000Res. 2017;6:2069. DOI: 10.12688/f1000research.11948.1van Kasteren Y.M., Schoemaker J. Premature ovarian failure : a systematic review on therapeutic interventions to restore ovarian function and achieve pregnancy. Hum. Reprod. Update. 1999;5:483–492. DOI: 10.1093/humupd/5.5.483van Kasteren Y.M., Schoemaker J. Premature ovarian failure : a systematic review on therapeutic interventions to restore ovarian function and achieve pregnancy. Hum. Reprod. Update. 1999;5:483–492. DOI: 10.1093/humupd/5.5.483Luisi S., Orlandini C., Regini C. et al. Premature ovarian insufficiency: from pathogenesis to clinical management. J. Endocrinol. Invest. 2015;38(6):597–603. DOI: 10.1007/s40618-014-0231-1Luisi S., Orlandini C., Regini C. et al. Premature ovarian insufficiency: from pathogenesis to clinical management. J. Endocrinol. Invest. 2015;38(6):597–603. DOI: 10.1007/s40618-014-0231-1Sullivan S.D., Sarrel P.M., Nelson L.M. Hormone replacement therapy in young women with primary ovarian insufficiency and early menopause. Fertil. Steril. 2016;106(7):1588–1599. DOI: 10.1016/j.fertnstert.2016.09.046Sullivan S.D., Sarrel P.M., Nelson L.M. Hormone replacement therapy in young women with primary ovarian insufficiency and early menopause. Fertil. Steril. 2016;106(7):1588–1599. DOI: 10.1016/j.fertnstert.2016.09.046Kawamura K. Cheng Y., Suzuki N. et al. Hippo signaling disruption and Akt stimulation of ovarian follicles for infertility treatment. Proc. Natl. Acad. Sci. U S A. 2013;110(43):17474–17479. DOI: 10.1073/pnas.1312830110Kawamura K. Cheng Y., Suzuki N. et al. Hippo signaling disruption and Akt stimulation of ovarian follicles for infertility treatment. Proc. Natl. Acad. Sci. U S A. 2013;110(43):17474–17479. DOI: 10.1073/pnas.1312830110Ethics Committee of American Society for Reproductive Medicine. Fertility preservation and reproduction in patients facing gonadotoxic therapies: a committee opinion. Fertil. Steril. 2013;100(5):1224–1231. DOI: 10.1016/j.fertnstert.2013.08.041Ethics Committee of American Society for Reproductive Medicine. Fertility preservation and reproduction in patients facing gonadotoxic therapies: a committee opinion. Fertil. Steril. 2013;100(5):1224–1231. DOI: 10.1016/j.fertnstert.2013.08.041Grieve K.M., McLaughlin M., Dunlop C.E. et al. The controversial existence and functional potential of oogonial stem cells. Maturitas. 2015;82(3):278–281. DOI: 10.1016/j.maturitas.2015.07.017Grieve K.M., McLaughlin M., Dunlop C.E. et al. The controversial existence and functional potential of oogonial stem cells. Maturitas. 2015;82(3):278–281. DOI: 10.1016/j.maturitas.2015.07.017Chu M.C., Rath K.M., Huie J., Taylor H.S. Elevated basal FSH in normal cycling women is associated with unfavourable lipid levels and increased cardiovascular risk. Hum. Reprod. 2003;18:1570–1573. DOI: 10.1093/humrep/deg330Chu M.C., Rath K.M., Huie J., Taylor H.S. Elevated basal FSH in normal cycling women is associated with unfavourable lipid levels and increased cardiovascular risk. Hum. Reprod. 2003;18:1570–1573. DOI: 10.1093/humrep/deg330Fenton A.J. Premature ovarian insufficiency: Pathogenesis and management. J. Midlife Health. 2015;6(4):147–153. DOI: 10.4103/0976-7800.172292Fenton A.J. Premature ovarian insufficiency: Pathogenesis and management. J. Midlife Health. 2015;6(4):147–153. DOI: 10.4103/0976-7800.172292Muka T., Oliver-Williams C., Kunutsor S. et al. Association of age at onset of menopause and time since onset of menopause with cardiovascular outcomes, intermediate vascular traits, and all-cause mortality : a systematic review and meta-analysis. JAMA Cardiol. 2016;1(7):767–776. DOI: 10.1001/jamacardio.2016.2415Muka T., Oliver-Williams C., Kunutsor S. et al. Association of age at onset of menopause and time since onset of menopause with cardiovascular outcomes, intermediate vascular traits, and all-cause mortality : a systematic review and meta-analysis. JAMA Cardiol. 2016;1(7):767–776. DOI: 10.1001/jamacardio.2016.2415Podfigurna A., Stellmach A., Szeliga A. et al. Metabolic profile of patients with premature ovarian insufficiency. J. Clin. Med. 2018;7(10): E374. DOI: 10.3390/jcm7100374Podfigurna A., Stellmach A., Szeliga A. et al. Metabolic profile of patients with premature ovarian insufficiency. J. Clin. Med. 2018;7(10): E374. DOI: 10.3390/jcm7100374Rahman I., Akesson A., Wolk A. Relationship between age at natural menopause and risk of heart failure. Menopause. 2015;22:12–16. DOI: 10.1097/GME.0000000000000261Rahman I., Akesson A., Wolk A. Relationship between age at natural menopause and risk of heart failure. Menopause. 2015;22:12–16. DOI: 10.1097/GME.0000000000000261Kuylaksizoglu M., Ipeka S., Kebapcilar L. et al. Risk factors for diabetes mellitus in women with premature ovarian insufficiency. Biol. Trace Elim. Rep. 2013;154(3):313–320. DOI: 10.1007/s12011-013-9738-0Kuylaksizoglu M., Ipeka S., Kebapcilar L. et al. Risk factors for diabetes mellitus in women with premature ovarian insufficiency. Biol. Trace Elim. Rep. 2013;154(3):313–320. DOI: 10.1007/s12011-013-9738-0Langrish J.P., Mills N.L., Bath L.E. et al. Cardiovascular effects of physiological and standard sex steroid replacement regimens in premature ovarian failure. Hypertension.;53(5):805–811. DOI: 10.1161/HYPERTENSIONAHA.108.126516Langrish J.P., Mills N.L., Bath L.E. et al. Cardiovascular effects of physiological and standard sex steroid replacement regimens in premature ovarian failure. Hypertension.;53(5):805–811. DOI: 10.1161/HYPERTENSIONAHA.108.126516Ostberg J.E., Storry C., Donald A.E. et al. A dose-response study of hormone replacement in young hypogonadal women: effects on intima media thickness and metabol- ism. Clin. Endocrinol. 2007;66:557–464. DOI: 10.1111/j.1365-2265.2007.02772.xOstberg J.E., Storry C., Donald A.E. et al. A dose-response study of hormone replacement in young hypogonadal women: effects on intima media thickness and metabol- ism. Clin. Endocrinol. 2007;66:557–464. DOI: 10.1111/j.1365-2265.2007.02772.xEl Khoudary S.R. Gaps, limitations and new insights on endogenous estrogen and follicle stimulating hormone as related to risk of cardiovascular disease in women traversing the menopause : A narrative review. Maturitas. 2017;104:44–53. DOI: 10.1016/j.maturitas.2017.08.003El Khoudary S.R. Gaps, limitations and new insights on endogenous estrogen and follicle stimulating hormone as related to risk of cardiovascular disease in women traversing the menopause : A narrative review. Maturitas. 2017;104:44–53. DOI: 10.1016/j.maturitas.2017.08.003Giordano S., Hage F.G., Xing D. et al. Estrogen and cardiovascular disease: is timing everything? Am. J. Med. Sci. 2015;350(1):27–35. DOI: 10.1097/MAJ.0000000000000512Giordano S., Hage F.G., Xing D. et al. Estrogen and cardiovascular disease: is timing everything? Am. J. Med. Sci. 2015;350(1):27–35. DOI: 10.1097/MAJ.0000000000000512Maclaran K., Panay N. Current concepts in premature ovarian insufficiency. Womens Health (Lond). 2015;11(2):169–182. DOI: 10.2217/whe.14.82Maclaran K., Panay N. Current concepts in premature ovarian insufficiency. Womens Health (Lond). 2015;11(2):169–182. DOI: 10.2217/whe.14.82Hamoda H. The British Menopause Society and Women’s Health Concern recommendations on the management of women with premature ovarian insufficiency. Post. Reprod. Health. 2017;23(1):22–35. DOI: 10.1177/2053369117699358Hamoda H. The British Menopause Society and Women’s Health Concern recommendations on the management of women with premature ovarian insufficiency. Post. Reprod. Health. 2017;23(1):22–35. DOI: 10.1177/2053369117699358Sassarini J., Lumsden M.A., Critchley H.O. Sex hormone replacement in ovarian failure e new treatment concepts. Best Pract. Res. Clin. Endocrinol. Metab. 2015;29(1):105–114. DOI: 10.1016/j.beem.2014.09.010Sassarini J., Lumsden M.A., Critchley H.O. Sex hormone replacement in ovarian failure e new treatment concepts. Best Pract. Res. Clin. Endocrinol. Metab. 2015;29(1):105–114. DOI: 10.1016/j.beem.2014.09.010Bachelot A., Nicolas C., Gricourt S. et al. Poor compliance to hormone therapy and decreased bone mineral density in women with premature ovarian insufficiency. PLoS One. 2016;11:e0164638. DOI: 10.1371/journal.pone.0164638Bachelot A., Nicolas C., Gricourt S. et al. Poor compliance to hormone therapy and decreased bone mineral density in women with premature ovarian insufficiency. PLoS One. 2016;11:e0164638. DOI: 10.1371/journal.pone.0164638Xu X., Jones M., Mishra G.D. Age at natural menopause and development of chronic conditions and multimorbidity: results from an Australian prospective cohort. Hum. Reprod. 2020;35:203–211. DOI: 10.1093/humrep/dez259Xu X., Jones M., Mishra G.D. Age at natural menopause and development of chronic conditions and multimorbidity: results from an Australian prospective cohort. Hum. Reprod. 2020;35:203–211. DOI: 10.1093/humrep/dez259Popat V.B., Calis K.A., Kalantaridou S.N. et al. Bone mineral density in young women with primary ovarian insufficiency: results of a three-year randomized controlled trial of physiological transdermal estradiol and testosterone replacement. J. Clin. Endocrinol. Metab. 2014;99(9):3418–3426. DOI: 10.1210/jc.2013-4145Popat V.B., Calis K.A., Kalantaridou S.N. et al. Bone mineral density in young women with primary ovarian insufficiency: results of a three-year randomized controlled trial of physiological transdermal estradiol and testosterone replacement. J. Clin. Endocrinol. Metab. 2014;99(9):3418–3426. DOI: 10.1210/jc.2013-4145Shah S., Nguyen H.H., Vincent A.J. Care of the adult woman with Turner syndrome. Climacteric. 2018;21(5):428–436. DOI: 10.1080/13697137.2018.1476969Shah S., Nguyen H.H., Vincent A.J. Care of the adult woman with Turner syndrome. Climacteric. 2018;21(5):428–436. DOI: 10.1080/13697137.2018.1476969Manolaga S.C. The role of estrogen and androgen receptors in bone health and disease. Nat. Rev. Endocrinol. 2013;9(12):699–712. DOI: 10.1038/nrendo.2013.179Manolaga S.C. The role of estrogen and androgen receptors in bone health and disease. Nat. Rev. Endocrinol. 2013;9(12):699–712. DOI: 10.1038/nrendo.2013.179Burgos N., Cintron D., Latortue-Albino P. et al. Estrogen-based hormone therapy in women with primary ovarian insufficiency : a systematic review. Endocrine. 2017;58(3):413–425. DOI: 10.1007/s12020-017-1435-xBurgos N., Cintron D., Latortue-Albino P. et al. Estrogen-based hormone therapy in women with primary ovarian insufficiency : a systematic review. Endocrine. 2017;58(3):413–425. DOI: 10.1007/s12020-017-1435-xCintron D., Rodriguez-Gutierrez R., Serrano V. et al. Effect of estrogen replacement therapy on bone and cardiovascular outcomes in women with Turner syndrome : a systematic review and meta-analysis. Endocrine. 2017;55(2):366–375. DOI: 10.1007/s12020-016-1046-yCintron D., Rodriguez-Gutierrez R., Serrano V. et al. Effect of estrogen replacement therapy on bone and cardiovascular outcomes in women with Turner syndrome : a systematic review and meta-analysis. Endocrine. 2017;55(2):366–375. DOI: 10.1007/s12020-016-1046-yCui X., Cui Y., Shi L. et al. A basic understanding of Turner syndrome: Incidence, complications, diagnosis, and treatment. Intractable Rare Dis. Res. 2018;7(4):223–228. DOI: 10.5582/irdr.2017.01056Cui X., Cui Y., Shi L. et al. A basic understanding of Turner syndrome: Incidence, complications, diagnosis, and treatment. Intractable Rare Dis. Res. 2018;7(4):223–228. DOI: 10.5582/irdr.2017.01056Benetti-Pinto C.L., Ferreira V.B., Yela D.A. Long-term follow-up of bone density in women with primary ovarian insufficiency. Menopause. 2015;22(9):946–949. DOI: 10.1097/GME.0000000000000445Benetti-Pinto C.L., Ferreira V.B., Yela D.A. Long-term follow-up of bone density in women with primary ovarian insufficiency. Menopause. 2015;22(9):946–949. DOI: 10.1097/GME.0000000000000445Popat V.B., Calis K.A., Kalantaridou S.N. et al. Bone mineral density in young women with primary ovarian insufficiency: results of a three-year randomized controlled trial of physiological transdermal estradiol and testosterone replacement. J. Clin. Endocrinol. Metab. 2014;99(9):3418–3426. DOI: 10.1210/jc.2013-4145Popat V.B., Calis K.A., Kalantaridou S.N. et al. Bone mineral density in young women with primary ovarian insufficiency: results of a three-year randomized controlled trial of physiological transdermal estradiol and testosterone replacement. J. Clin. Endocrinol. Metab. 2014;99(9):3418–3426. DOI: 10.1210/jc.2013-4145Zuckerman-Levin N., Frolova-Bishara T., Militianu D. et al. Androgen replacement therapy in Turner syndrome: a pilot study. J. Clin. Endocrinol. Metab. 2009;94(12): 4820–4827. DOI: 10.1210/jc.2009-0514Zuckerman-Levin N., Frolova-Bishara T., Militianu D. et al. Androgen replacement therapy in Turner syndrome: a pilot study. J. Clin. Endocrinol. Metab. 2009;94(12): 4820–4827. DOI: 10.1210/jc.2009-0514Hewlett M., Mahalingaiah S. Update on primary ovarian insufficiency. Curr. Opin. Endocrinol. Diabetes Obes. 2015;22(6):483–489. DOI: 10.1097/MED.0000000000000206Hewlett M., Mahalingaiah S. Update on primary ovarian insufficiency. Curr. Opin. Endocrinol. Diabetes Obes. 2015;22(6):483–489. DOI: 10.1097/MED.0000000000000206Nappi R.E., Cucinella L., Martini E. et al. Sexuality in premature ovarian insufficiency. Climacteric. 2019;22:289–295. DOI: 10.1080/13697137.2019.1575356Nappi R.E., Cucinella L., Martini E. et al. Sexuality in premature ovarian insufficiency. Climacteric. 2019;22:289–295. DOI: 10.1080/13697137.2019.1575356van der Stege J.G., Groen H., van Zadelhoff S.J. et al. Decreased androgen concentrations and diminished general and sexual well-being in women with premature ovarian failure. Menopause. 2008;15(1):23–31. DOI: 10.1097/gme.0b013e3180f6108cvan der Stege J.G., Groen H., van Zadelhoff S.J. et al. Decreased androgen concentrations and diminished general and sexual well-being in women with premature ovarian failure. Menopause. 2008;15(1):23–31. DOI: 10.1097/gme.0b013e3180f6108cDe Almeida D.M., Benetti-Pinto C.L., Makuch M.Y. Sexual function of women with premature ovarian failure. Menopause. 2011;18(3):262–266. DOI: 10.1097/gme.0b013e3181f4318dDe Almeida D.M., Benetti-Pinto C.L., Makuch M.Y. Sexual function of women with premature ovarian failure. Menopause. 2011;18(3):262–266. DOI: 10.1097/gme.0b013e3181f4318dSchmidt P.J., Luff J.A., Haq N.A. et al. Depression in women with spontaneous 46,XX primary ovarian insufficiency. J. Clin. Endocrinol. Metab. 2011;96(2):E278–E287. DOI: 10.1210/jc.2010-0613Schmidt P.J., Luff J.A., Haq N.A. et al. Depression in women with spontaneous 46,XX primary ovarian insufficiency. J. Clin. Endocrinol. Metab. 2011;96(2):E278–E287. DOI: 10.1210/jc.2010-0613Liao K.L., Wood N., Conway G.S. Premature menopause and psychological well-being. J. Psychosom. Obstet. Gynaecol. 2000;21(3):167–174. DOI: 10.3109/01674820009075624Liao K.L., Wood N., Conway G.S. Premature menopause and psychological well-being. J. Psychosom. Obstet. Gynaecol. 2000;21(3):167–174. DOI: 10.3109/01674820009075624Mann E., Singer D., Pitkin J. et al. Psychosocial adjustment in women with premature menopause: a cross-sectional survey. Climacteric. 2012;15(5):481–489. DOI: 10.3109/13697137.2011.647841Mann E., Singer D., Pitkin J. et al. Psychosocial adjustment in women with premature menopause: a cross-sectional survey. Climacteric. 2012;15(5):481–489. DOI: 10.3109/13697137.2011.647841Аверкова В.Г., Юренева С.В. Оценка качества жизни пациенток с преждевременной недостаточностью яичников, принимающих заместительную гормональную терапию. Акушерство и гинекология. 2023;(5):50–58. DOI: 10.18565/aig.2023.16Averkova V.G., Yureneva S.V. Quality of life in patients with premature ovarian insufficiency treated with hormone replacement therapy. Obstetrics and Gynecology. 2023;(5):50–58. DOI: 10.18565/aig.2023.16Calik-Ksepka A., Grymowicz M., Rudnicka E. et al. Signs and symptoms, evaluation, and management of genitourinary tract consequences of premature ovarian insufficiency. Prz Menopauzalny. 2018;17(3):131–134. DOI: 10.5114/pm.2018.78558Calik-Ksepka A., Grymowicz M., Rudnicka E. et al. Signs and symptoms, evaluation, and management of genitourinary tract consequences of premature ovarian insufficiency. Prz Menopauzalny. 2018;17(3):131–134. DOI: 10.5114/pm.2018.78558Faubion S.S., Sood R., Kapoor E. Genitourinary syndrome of menopause: management strategies for the clinician. Mayo Clin. Proc. 2017;92(12):1842–1849. DOI: 10.1016/j.mayocp.2017.08.019Faubion S.S., Sood R., Kapoor E. Genitourinary syndrome of menopause: management strategies for the clinician. Mayo Clin. Proc. 2017;92(12):1842–1849. DOI: 10.1016/j.mayocp.2017.08.019Bonetti-Pinto C.L., Giraldo P.C., Pacello P.C.C. et al. Vaginal epithelium and microflora characteristics in women with premature ovarian failure under hormone therapy compared to healthy women. Arch. Gynecol. Obstet. 2015;292:159–164. DOI: 10.1007/s00404-015-3616-2Bonetti-Pinto C.L., Giraldo P.C., Pacello P.C.C. et al. Vaginal epithelium and microflora characteristics in women with premature ovarian failure under hormone therapy compared to healthy women. Arch. Gynecol. Obstet. 2015;292:159–164. DOI: 10.1007/s00404-015-3616-2Rocca W.A., Bower J.H., Maraganore D.M. et al. Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Neurology. 2007;69(11):1074–1083. DOI: 10.1212/01.wnl.0000276984.19542.e6Rocca W.A., Bower J.H., Maraganore D.M. et al. Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Neurology. 2007;69(11):1074–1083. DOI: 10.1212/01.wnl.0000276984.19542.e6Bove R., Secor E., Chibnik L.B. et al. Age at surgical menopause influences cognitive decline and Alzheimer pathology in older women. Neurology. 2014;82(3):222–229. DOI: 10.1212/WNL.0000000000000033Bove R., Secor E., Chibnik L.B. et al. Age at surgical menopause influences cognitive decline and Alzheimer pathology in older women. Neurology. 2014;82(3):222–229. DOI: 10.1212/WNL.0000000000000033

The authors declare that there are no conflicts of interest present.